Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Parkinson Disease, Secondary”

138 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 138 results

Post-approval studies (Phase 4)Study completedNCT04489888
What this trial is testing

Pembrolizumab (MK-3475) Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (MK-3475-B10/KEYNOTE B10)

Who this might be right for
Squamous Cell Carcinoma of Head and Neck
Merck Sharp & Dohme LLC 101
Large-scale testing (Phase 3)Study completedNCT02819518
What this trial is testing

Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355)

Who this might be right for
Triple Negative Breast Cancer (TNBC)
Merck Sharp & Dohme LLC 882
Large-scale testing (Phase 3)Study completedNCT04246177
What this trial is testing

Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)

Who this might be right for
Carcinoma, Hepatocellular
Merck Sharp & Dohme LLC 479
Large-scale testing (Phase 3)Study completedNCT04934722
What this trial is testing

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension

Who this might be right for
Metastatic Hormone-Sensitive Prostate Cancer
Merck Sharp & Dohme LLC 186
Not applicableUnknownNCT05273957
What this trial is testing

A Model of Hospital-Territory Management Coordinated by a Case Manager to Improve the Care of Patients With Parkinsonism.

Who this might be right for
Parkinson DiseaseAtypical ParkinsonismSecondary Parkinsonism+2 more
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta 121
Testing effectiveness (Phase 2)Looking for participantsNCT07252739
What this trial is testing

KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

Who this might be right for
Malignant Neoplasm
Merck Sharp & Dohme LLC 130
Large-scale testing (Phase 3)Study completedNCT03976323
What this trial is testing

Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)

Who this might be right for
Carcinoma, Nonsquamous Non-small-cell Lung
Merck Sharp & Dohme LLC 1,003
Large-scale testing (Phase 3)Study completedNCT02358031
What this trial is testing

Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)

Who this might be right for
Recurrent Head and Neck CancerMetastatic Head and Neck Cancer
Merck Sharp & Dohme LLC 882
Large-scale testing (Phase 3)Study completedNCT03635567
What this trial is testing

Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)

Who this might be right for
Cervical Cancer
Merck Sharp & Dohme LLC 617
Large-scale testing (Phase 3)Study completedNCT03976375
What this trial is testing

Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)

Who this might be right for
Metastatic Non-Small Cell Lung Cancer
Merck Sharp & Dohme LLC 422
Testing effectiveness (Phase 2)Active Not RecruitingNCT06671938
What this trial is testing

Safety, Tolerability, and Pharmacokinetics of Exidavnemab in Patients With Parkinson's Disease and Patients With Multiple System Atrophy

Who this might be right for
Parkinson DiseaseMultiple System Atrophy
BioArctic AB 38
Large-scale testing (Phase 3)Study completedNCT03898180
What this trial is testing

Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)

Who this might be right for
Urothelial Carcinoma
Merck Sharp & Dohme LLC 505
Testing effectiveness (Phase 2)Study completedNCT02787005
What this trial is testing

Study of Pembrolizumab (MK-3475) in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)(MK-3475-199/KEYNOTE-199)

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Merck Sharp & Dohme LLC 388
Large-scale testing (Phase 3)Study completedNCT03834519
What this trial is testing

Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)

Who this might be right for
Prostatic Neoplasms
Merck Sharp & Dohme LLC 793
Testing effectiveness (Phase 2)Study completedNCT03993353
What this trial is testing

Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer

Who this might be right for
Head and Neck CancerHead and Neck Squamous Cell CarcinomaHead and Neck Carcinoma+9 more
University of California, San Diego 7
Large-scale testing (Phase 3)Active Not RecruitingNCT04956692
What this trial is testing

Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)

Who this might be right for
Non-Small Cell Lung Cancer
Merck Sharp & Dohme LLC 531
Early research (Phase 1)Study completedNCT02618941
What this trial is testing

Follow-up Study to Assess a Second Boost Immunization With AFFITOPE® PD01A With Regard to Safety and Clinical Activity (AFF008AA)

Who this might be right for
Parkinson's Disease
Affiris AG 26
Large-scale testing (Phase 3)Active Not RecruitingNCT03834493
What this trial is testing

Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)

Who this might be right for
Prostatic Neoplasms
Merck Sharp & Dohme LLC 1,244
Testing effectiveness (Phase 2)Active Not RecruitingNCT06483334
What this trial is testing

Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)

Who this might be right for
Metastatic Urothelial CarcinomaLocally Advanced Urothelial Carcinoma
Merck Sharp & Dohme LLC 38
Early research (Phase 1)WithdrawnNCT03920839
What this trial is testing

INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105)

Who this might be right for
Advanced and/or Metastatic Solid TumorsStage IIIB Not Amenable to Curative Therapy to Stage IV Non-small Cell Lung CancerAdvanced/Metastatic Unresectable Malignant Pleural Mesothelioma
Incyte Corporation
Load More Results